New Jersey Assembly Bill A2183

New Jersey 2022-2023 Regular Session

• Introduced: 2/7/22
• Refer: 2/7/22

Caption

Prohibits payment of more than one copayment, coinsurance or deductible for series of vaccinations used in preventive treatment of rabies under certain health benefits plans.

Impact

If enacted, A2183 would impact state laws regarding health insurance and emergency medical care. The bill amends existing provisions within the 'Health Care Quality Act' to ensure that patients receiving preventive rabies vaccinations are not deterred by costs. This legislative change could encourage more individuals who have potential exposure to rabies to seek timely treatment, enhancing public health and safety by mitigating the risk of rabies outbreaks. Additionally, the bill applies to various health benefits programs, thereby affecting a broad segment of the state’s population under these plans.

Summary

Assembly Bill A2183 aims to address the financial burden associated with rabies vaccination treatments under health benefits plans. Specifically, the bill prohibits the collection of more than one copayment, coinsurance, or deductible for a series of rabies vaccinations administered in a hospital emergency setting over a period of 180 days. This is important because the rabies vaccine is primarily administered in emergency rooms, often leading to significant medical costs due to multiple visits that incur high copayments. By imposing this limit on payments, the bill seeks to facilitate access to necessary medical treatment without the financial obstacle of additional costs for follow-up visits related to the vaccinations.

Contention

While the bill is likely to gain support from those advocating for accessible healthcare and animal control measures, potential contention may arise from insurance providers concerned about the implications for their coverage policies. The limitation on copayments could provoke debate regarding the financial sustainability of health benefits plans and the role of insurance companies in funding necessary procedures. Stakeholders may discuss whether the bill ensures adequate coverage without imposing additional costs on insurers, balancing public health interests with the economic viability of health insurance offerings.